SCHEMBL13615338

SCHEMBL13615338

Cc1cc(NS(=O)(=O)c2ccc(Cl)cc2Cl)ccc1C(C)(C)C

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PPARG P37231 8/20 0.56
CDK1 P06493 1/20 0.56
CCNB1 P14635 1/20 0.56
CCNA2 P20248 1/20 0.56
CDK2 P24941 1/20 0.56
CDK7 P50613 1/20 0.56
CCNH P51946 1/20 0.56
CCNA1 P78396 1/20 0.56
ITGA1 P56199 4/20 0.54
LMNA P02545 2/20 0.52
MAPT P10636 2/20 0.52
MEN1 O00255 1/20 0.52
ALOX12 P18054 1/20 0.52
KMT2A Q03164 1/20 0.52
NLRP1 Q9C000 1/20 0.52
HDAC1 Q13547 1/20 0.48
HDAC8 Q9BY41 1/20 0.48
EDNRA P25101 2/20 0.48
CYP3A4 P08684 1/20 0.46
ALDH1A1 P00352 2/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13615072 0.89 CDK1 (0.63) CDK1CCNB1CCNA2CDK2CDK7
SCHEMBL13615118 0.87 BRD4 (0.51) PPARGCDK1CCNB1CCNA2CDK2
SCHEMBL16325537 0.86 CDK1 (0.65) PPARGCDK1CCNB1CCNA2CDK2
SCHEMBL13615225 0.85 PPARG (0.55) PPARGCDK1CCNB1CCNA2CDK2
SCHEMBL13615035 0.85 SLC22A12 (0.54) CDK1CCNB1CCNA2CDK2CDK7
SCHEMBL13615121 0.85 CDK1 (0.52) PPARGCDK1CCNB1CCNA2CDK2
SCHEMBL13615230 0.84 SLC22A12 (0.48) PPARGCDK1CCNB1CCNA2CDK2
SCHEMBL13615103 0.83 CES1 (0.58) CDK1CCNB1CCNA2CDK2CDK7
SCHEMBL13615086 0.81 PKM (0.55) CDK1CCNB1CCNA2CDK2CDK7
SCHEMBL13615029 0.80 ALDH1A1 (0.59) CDK1CCNB1CCNA2CDK2CDK7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090275593-A1 3 Substituted N-(aryl- or heteroaryl)-pyrazolo[1,5-a]pyrimidines as Kinase Inhibitors NOVARTIS AG 2009-11-05 US disclosed
US-20090118277-A1 3 Unsubstituted N-(aryl- or heteroaryl)-pyrazolo[1,5-a]pyrimidines as Kinase Inhibitors NOVARTIS AG 2009-05-07 US disclosed
US-20090118277-A1 3 Unsubstituted N-(aryl- or heteroaryl)-pyrazolo[1,5-a]pyrimidines as Kinase Inhibitors NOVARTIS AG 2009-05-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090118277-A1 3 Unsubstituted N-(aryl- or heteroaryl)-pyrazolo[1,5-a]pyrimidines as Kinase Inhibitors TIE1, TEK, MATK PPARG 1772/4885CDK1 339/4885CCNB1 2488/4885
US-20090275593-A1 3 Substituted N-(aryl- or heteroaryl)-pyrazolo[1,5-a]pyrimidines as Kinase Inhibitors TIE1, TEK, MATK PPARG 1808/4885CDK1 311/4885CCNB1 2524/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.